Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Why Shares of Mesoblast Are Down Monday
12:01pm, Monday, 07'th Aug 2023
Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bone marrow from healthy donors.
Why Shares of Mesoblast Are Plunging Friday
02:46pm, Friday, 04'th Aug 2023
Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was given a Complete Response Letter by the FDA.
FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
10:01pm, Thursday, 03'rd Aug 2023
The U.S. Food and Drug Administration had rejected Mesoblast's , cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transp
Best Momentum Stocks to Buy for July 26th
11:43am, Wednesday, 26'th Jul 2023
IAS, MESO and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 26, 2023.
Are You Looking for a Top Momentum Pick? Why Mesoblast Limited (MESO) is a Great Choice
01:24pm, Friday, 23'rd Jun 2023
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
10:32am, Tuesday, 13'th Jun 2023
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND
Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript
11:38pm, Thursday, 25'th May 2023
Mesoblast Limited (NASDAQ:MESO ) Q3 2023 Earnings Conference Call May 25, 2023 6:30 PM ET Company Participants Silviu Itescu – Chief Executive Officer Eric Rose – Chief Medical Officer Andrew Chap
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
08:24am, Thursday, 09'th Mar 2023
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft
Mesoblast Limited. (MESO) Q2 2023 Earnings Call Transcript
04:21am, Thursday, 02'nd Mar 2023
Mesoblast Limited. (NASDAQ:MESO ) Q2 2023 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Silviu Itescu – Chief Executive Officer Andrew Chaponnel – Chief Financial Offi
Mesoblast Financial Results and Corporate Update Webcast
07:38pm, Sunday, 26'th Feb 2023
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 15'th Dec 2022
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mesoblast Limited (MESO) Q1 2023 Earnings Call Transcript
08:50am, Wednesday, 23'rd Nov 2022
Mesoblast Limited (NASDAQ:MESO ) Q1 2023 Results Conference Call November 22, 2022 4:30 PM ET Company Participants Dr. Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Dr. Eric Rose - Chief M
Mesoblast Financial Results and Corporate Update Webcast
06:00am, Monday, 21'st Nov 2022
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
10:28pm, Tuesday, 30'th Aug 2022
Mesoblast Limited (NASDAQ:MESO ) Q4 2022 Earnings Conference Call August 30, 2022 6:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose - Chief Medical Of
Mesoblast Corporate Update and Financial Results Webcast
08:14pm, Monday, 29'th Aug 2022
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
